Since the introduction of intravitreal anti-VEGF injections for various retinal conditions such as diabetic retinopathy, retinal vein occlusion, and neovascular age-related macular degeneration, these injections have become the first choice of treatment, replacing other conventional therapies like laser. The gene discussed is VEGFA; the disease is diabetic retinopathy.